Prof Takeuchi on DMARDs treatment and regional disparities For similar dose, serum concentration of the polyglutamate (active) form of MTX is much higher in Japanese than US patients And also high levels achieved much quicker in Japanese than US patients This is strong https://t.co/ikp63wWifj

What’s new in RA Pathogenesis in #APLAR25 by Ellen Gravellese Take home message: there is still hope for synovial biopsies to be a biomarker for prediction of response to treatment As a synovial biopsy expert, I am not convinced of this one, but time will tell @APLAR_org https://t.co/EEw5ncKa1r

Can we prevent #rheumatoidarthritis? Dr. Gravallese shares this interesting slide that summarizes the different disease prevention trials in RA…..they have managed to delay disease onset but prevention is still in question. @RheumNow #APLAR25 @rheumarhyme @marklagacmd https://t.co/qhGYnNL5Ek

📍Smoking, obesity and low Vit D are significant risk factors for Pre-RA. 📍Subdoligranulum arthritogenic strain is a newly described infectious agent implicated in the pathogenesis of pre-RA @RheumNow #ACR25 @rheumarhyme https://t.co/ZzZZlfdKmk

QD Clinic: Rapidly progressive RA ILD - or not? Dr. Richard Conway, a rheumatologist in Dublin, Ireland, discusses whether this case shows rapidly progressing RA-ILD, or not, as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September 2025. https://t.co/YC8XFiqZmd

Rheumatoid Arthritis ILD Complications https://t.co/gAZCGTwHLB https://t.co/qcMmDuxXYx

Abatacept and Methotrexate may Lower Risk of Interstitial Lung Disease in RA A post hoc, pooled analysis of of rheumatoid arthritis (RA) clinical trials shows those received abatacept had a lower rate of Interstitial lung disease (ILD). https://t.co/3AISriCUeC https://t.co/nN03e4ZBDU

🌐 ILD Treatment Guidelines – LIVE Webinar 📅 Sept 9 (TOMORROW!) | ⏰ 7PM EST An expert panel reviews ACR & EULAR guidance and looks ahead at emerging therapies. Speakers: Drs. Sindhu Johnson, Anna-Maria Hoffmann-Vold, Scott Matson & Jack Cush, Moderator https://t.co/iQj8OstJDU https://t.co/WsN5vntKhH

Ellen Gravallese update on RA pathogenesis Her take on RA interception studies “While drug repurposing has not proven capable of preventing transition from Pre RA to RA, we need to better understand disease mechanisms to offer other interventions” @RheumNow #APLAR25 @APLAR_org https://t.co/d39ihVvWyA

One of the most impt updates recommended to add a bDMARD if tx target is not achieved by the 1st csDMARD (no more prognostic stratification) But, accdg to Dr. Smolen, adding a 2nd csDMARD should still be considered especially in resource-limited countries. @RheumNow #APLAR25 https://t.co/ZQiviGcrYp

Dr. Josef Smolen discusses 2025 EULAR updates for RA. He highlighted the importance of OP A - that tx should be a shared decision making between px and rheuma in order to ensure better care and disease control. @RheumNow #aplar25 #APLAR25 https://t.co/KOJbiK87TS

Methotrexate significantly lowers Systolic BP Australian researchers have shown that methotrexate (MTX) has another secondary, beneficial effect by significantly lowering systolic blood pressure, and contributes to its well docuented cardioprotive effecs. https://t.co/HDnDWahuul